Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Growth 2025-2031
The global Group A and Group C Meningococcal Polysaccharide Vaccine market size is predicted to grow from US$ 328 million in 2025 to US$ 467 million in 2031; it is expected to grow at a CAGR of 6.1% from 2025 to 2031.
After vaccination, the body can produce a humoral immune response. It is used to prevent infectious diseases caused by group A and group C meningococci, such as cerebrospinal meningitis and pneumonia.
Meningococcal disease, caused by Neisseria meningitidis, can cause serious illness and even death. The global burden of meningococcal disease, especially serogroups A and C, drives the need for effective vaccines to prevent these infections.
LP Information, Inc. (LPI) ' newest research report, the “Group A and Group C Meningococcal Polysaccharide Vaccine Industry Forecast” looks at past sales and reviews total world Group A and Group C Meningococcal Polysaccharide Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Group A and Group C Meningococcal Polysaccharide Vaccine sales for 2025 through 2031. With Group A and Group C Meningococcal Polysaccharide Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Group A and Group C Meningococcal Polysaccharide Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Group A and Group C Meningococcal Polysaccharide Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Group A and Group C Meningococcal Polysaccharide Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Group A and Group C Meningococcal Polysaccharide Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Group A and Group C Meningococcal Polysaccharide Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Group A and Group C Meningococcal Polysaccharide Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Group A and Group C Meningococcal Polysaccharide Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Group A and Group C Meningococcal Polysaccharide Vaccine market?
What factors are driving Group A and Group C Meningococcal Polysaccharide Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Group A and Group C Meningococcal Polysaccharide Vaccine market opportunities vary by end market size?
How does Group A and Group C Meningococcal Polysaccharide Vaccine break out by Type, by Application?
After vaccination, the body can produce a humoral immune response. It is used to prevent infectious diseases caused by group A and group C meningococci, such as cerebrospinal meningitis and pneumonia.
Meningococcal disease, caused by Neisseria meningitidis, can cause serious illness and even death. The global burden of meningococcal disease, especially serogroups A and C, drives the need for effective vaccines to prevent these infections.
LP Information, Inc. (LPI) ' newest research report, the “Group A and Group C Meningococcal Polysaccharide Vaccine Industry Forecast” looks at past sales and reviews total world Group A and Group C Meningococcal Polysaccharide Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Group A and Group C Meningococcal Polysaccharide Vaccine sales for 2025 through 2031. With Group A and Group C Meningococcal Polysaccharide Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Group A and Group C Meningococcal Polysaccharide Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Group A and Group C Meningococcal Polysaccharide Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Group A and Group C Meningococcal Polysaccharide Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Group A and Group C Meningococcal Polysaccharide Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Group A and Group C Meningococcal Polysaccharide Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Group A and Group C Meningococcal Polysaccharide Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Group A and Group C Meningococcal Polysaccharide Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Class 1 Vaccine
- Class II Vaccine
- Hospital
- Clinic
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Walvax
- Lanzhou Institute of Biological Products
- AIM Bio
- Sanofi Pasteur
- GSK
- Hualan Bio
- ZFSW
- Changsheng
- Kanghua Bio
What is the 10-year outlook for the global Group A and Group C Meningococcal Polysaccharide Vaccine market?
What factors are driving Group A and Group C Meningococcal Polysaccharide Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Group A and Group C Meningococcal Polysaccharide Vaccine market opportunities vary by end market size?
How does Group A and Group C Meningococcal Polysaccharide Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Group A and Group C Meningococcal Polysaccharide Vaccine by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Group A and Group C Meningococcal Polysaccharide Vaccine by Country/Region, 2020, 2024 & 2031
2.2 Group A and Group C Meningococcal Polysaccharide Vaccine Segment by Type
2.2.1 Class 1 Vaccine
2.2.2 Class II Vaccine
2.3 Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type
2.3.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2020-2025)
2.3.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue and Market Share by Type (2020-2025)
2.3.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Price by Type (2020-2025)
2.4 Group A and Group C Meningococcal Polysaccharide Vaccine Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application
2.5.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Market Share by Application (2020-2025)
2.5.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue and Market Share by Application (2020-2025)
2.5.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Breakdown Data by Company
3.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Sales by Company (2020-2025)
3.1.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Company (2020-2025)
3.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Revenue by Company (2020-2025)
3.2.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Company (2020-2025)
3.2.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Company (2020-2025)
3.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Price by Company
3.4 Key Manufacturers Group A and Group C Meningococcal Polysaccharide Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Group A and Group C Meningococcal Polysaccharide Vaccine Product Location Distribution
3.4.2 Players Group A and Group C Meningococcal Polysaccharide Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR GROUP A AND GROUP C MENINGOCOCCAL POLYSACCHARIDE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Geographic Region (2020-2025)
4.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country/Region (2020-2025)
4.2.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Sales by Country/Region (2020-2025)
4.2.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales Growth
4.4 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales Growth
4.5 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Growth
4.6 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Growth
5 AMERICAS
5.1 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country
5.1.1 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2025)
5.1.2 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2025)
5.2 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2025)
5.3 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Region
6.1.1 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Region (2020-2025)
6.1.2 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Region (2020-2025)
6.2 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2025)
6.3 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Group A and Group C Meningococcal Polysaccharide Vaccine by Country
7.1.1 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2025)
7.1.2 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2025)
7.2 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2025)
7.3 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine by Country
8.1.1 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2025)
8.1.2 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2025)
8.2 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2025)
8.3 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Group A and Group C Meningococcal Polysaccharide Vaccine
10.3 Manufacturing Process Analysis of Group A and Group C Meningococcal Polysaccharide Vaccine
10.4 Industry Chain Structure of Group A and Group C Meningococcal Polysaccharide Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Group A and Group C Meningococcal Polysaccharide Vaccine Distributors
11.3 Group A and Group C Meningococcal Polysaccharide Vaccine Customer
12 WORLD FORECAST REVIEW FOR GROUP A AND GROUP C MENINGOCOCCAL POLYSACCHARIDE VACCINE BY GEOGRAPHIC REGION
12.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Size Forecast by Region
12.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Forecast by Region (2026-2031)
12.1.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Group A and Group C Meningococcal Polysaccharide Vaccine Forecast by Type (2026-2031)
12.7 Global Group A and Group C Meningococcal Polysaccharide Vaccine Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Walvax
13.1.1 Walvax Company Information
13.1.2 Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.1.3 Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Walvax Main Business Overview
13.1.5 Walvax Latest Developments
13.2 Lanzhou Institute of Biological Products
13.2.1 Lanzhou Institute of Biological Products Company Information
13.2.2 Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.2.3 Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Lanzhou Institute of Biological Products Main Business Overview
13.2.5 Lanzhou Institute of Biological Products Latest Developments
13.3 AIM Bio
13.3.1 AIM Bio Company Information
13.3.2 AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.3.3 AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 AIM Bio Main Business Overview
13.3.5 AIM Bio Latest Developments
13.4 Sanofi Pasteur
13.4.1 Sanofi Pasteur Company Information
13.4.2 Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.4.3 Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Sanofi Pasteur Main Business Overview
13.4.5 Sanofi Pasteur Latest Developments
13.5 GSK
13.5.1 GSK Company Information
13.5.2 GSK Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.5.3 GSK Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 GSK Main Business Overview
13.5.5 GSK Latest Developments
13.6 Hualan Bio
13.6.1 Hualan Bio Company Information
13.6.2 Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.6.3 Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Hualan Bio Main Business Overview
13.6.5 Hualan Bio Latest Developments
13.7 ZFSW
13.7.1 ZFSW Company Information
13.7.2 ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.7.3 ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 ZFSW Main Business Overview
13.7.5 ZFSW Latest Developments
13.8 Changsheng
13.8.1 Changsheng Company Information
13.8.2 Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.8.3 Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Changsheng Main Business Overview
13.8.5 Changsheng Latest Developments
13.9 Kanghua Bio
13.9.1 Kanghua Bio Company Information
13.9.2 Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.9.3 Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Kanghua Bio Main Business Overview
13.9.5 Kanghua Bio Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Group A and Group C Meningococcal Polysaccharide Vaccine by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Group A and Group C Meningococcal Polysaccharide Vaccine by Country/Region, 2020, 2024 & 2031
2.2 Group A and Group C Meningococcal Polysaccharide Vaccine Segment by Type
2.2.1 Class 1 Vaccine
2.2.2 Class II Vaccine
2.3 Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type
2.3.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2020-2025)
2.3.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue and Market Share by Type (2020-2025)
2.3.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Price by Type (2020-2025)
2.4 Group A and Group C Meningococcal Polysaccharide Vaccine Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application
2.5.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Market Share by Application (2020-2025)
2.5.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue and Market Share by Application (2020-2025)
2.5.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Breakdown Data by Company
3.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Sales by Company (2020-2025)
3.1.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Company (2020-2025)
3.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Revenue by Company (2020-2025)
3.2.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Company (2020-2025)
3.2.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Company (2020-2025)
3.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Price by Company
3.4 Key Manufacturers Group A and Group C Meningococcal Polysaccharide Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Group A and Group C Meningococcal Polysaccharide Vaccine Product Location Distribution
3.4.2 Players Group A and Group C Meningococcal Polysaccharide Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR GROUP A AND GROUP C MENINGOCOCCAL POLYSACCHARIDE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Geographic Region (2020-2025)
4.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country/Region (2020-2025)
4.2.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Sales by Country/Region (2020-2025)
4.2.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales Growth
4.4 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales Growth
4.5 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Growth
4.6 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Growth
5 AMERICAS
5.1 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country
5.1.1 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2025)
5.1.2 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2025)
5.2 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2025)
5.3 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Region
6.1.1 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Region (2020-2025)
6.1.2 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Region (2020-2025)
6.2 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2025)
6.3 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Group A and Group C Meningococcal Polysaccharide Vaccine by Country
7.1.1 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2025)
7.1.2 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2025)
7.2 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2025)
7.3 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine by Country
8.1.1 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2025)
8.1.2 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2025)
8.2 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2025)
8.3 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Group A and Group C Meningococcal Polysaccharide Vaccine
10.3 Manufacturing Process Analysis of Group A and Group C Meningococcal Polysaccharide Vaccine
10.4 Industry Chain Structure of Group A and Group C Meningococcal Polysaccharide Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Group A and Group C Meningococcal Polysaccharide Vaccine Distributors
11.3 Group A and Group C Meningococcal Polysaccharide Vaccine Customer
12 WORLD FORECAST REVIEW FOR GROUP A AND GROUP C MENINGOCOCCAL POLYSACCHARIDE VACCINE BY GEOGRAPHIC REGION
12.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Size Forecast by Region
12.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Forecast by Region (2026-2031)
12.1.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Group A and Group C Meningococcal Polysaccharide Vaccine Forecast by Type (2026-2031)
12.7 Global Group A and Group C Meningococcal Polysaccharide Vaccine Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Walvax
13.1.1 Walvax Company Information
13.1.2 Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.1.3 Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Walvax Main Business Overview
13.1.5 Walvax Latest Developments
13.2 Lanzhou Institute of Biological Products
13.2.1 Lanzhou Institute of Biological Products Company Information
13.2.2 Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.2.3 Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Lanzhou Institute of Biological Products Main Business Overview
13.2.5 Lanzhou Institute of Biological Products Latest Developments
13.3 AIM Bio
13.3.1 AIM Bio Company Information
13.3.2 AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.3.3 AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 AIM Bio Main Business Overview
13.3.5 AIM Bio Latest Developments
13.4 Sanofi Pasteur
13.4.1 Sanofi Pasteur Company Information
13.4.2 Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.4.3 Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Sanofi Pasteur Main Business Overview
13.4.5 Sanofi Pasteur Latest Developments
13.5 GSK
13.5.1 GSK Company Information
13.5.2 GSK Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.5.3 GSK Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 GSK Main Business Overview
13.5.5 GSK Latest Developments
13.6 Hualan Bio
13.6.1 Hualan Bio Company Information
13.6.2 Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.6.3 Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Hualan Bio Main Business Overview
13.6.5 Hualan Bio Latest Developments
13.7 ZFSW
13.7.1 ZFSW Company Information
13.7.2 ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.7.3 ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 ZFSW Main Business Overview
13.7.5 ZFSW Latest Developments
13.8 Changsheng
13.8.1 Changsheng Company Information
13.8.2 Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.8.3 Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Changsheng Main Business Overview
13.8.5 Changsheng Latest Developments
13.9 Kanghua Bio
13.9.1 Kanghua Bio Company Information
13.9.2 Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.9.3 Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Kanghua Bio Main Business Overview
13.9.5 Kanghua Bio Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Group A and Group C Meningococcal Polysaccharide Vaccine Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Group A and Group C Meningococcal Polysaccharide Vaccine Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Class 1 Vaccine
Table 4. Major Players of Class II Vaccine
Table 5. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2025) & (K Units)
Table 6. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2020-2025)
Table 7. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Type (2020-2025) & ($ million)
Table 8. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2020-2025)
Table 9. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Price by Type (2020-2025) & (US$/Unit)
Table 10. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale by Application (2020-2025) & (K Units)
Table 11. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Market Share by Application (2020-2025)
Table 12. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Application (2020-2025) & ($ million)
Table 13. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2020-2025)
Table 14. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Price by Application (2020-2025) & (US$/Unit)
Table 15. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Company (2020-2025) & (K Units)
Table 16. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Company (2020-2025)
Table 17. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Company (2020-2025) & ($ millions)
Table 18. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Company (2020-2025)
Table 19. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Price by Company (2020-2025) & (US$/Unit)
Table 20. Key Manufacturers Group A and Group C Meningococcal Polysaccharide Vaccine Producing Area Distribution and Sales Area
Table 21. Players Group A and Group C Meningococcal Polysaccharide Vaccine Products Offered
Table 22. Group A and Group C Meningococcal Polysaccharide Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Geographic Region (2020-2025) & (K Units)
Table 26. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share Geographic Region (2020-2025)
Table 27. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Geographic Region (2020-2025) & ($ millions)
Table 28. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Geographic Region (2020-2025)
Table 29. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country/Region (2020-2025) & (K Units)
Table 30. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Country/Region (2020-2025)
Table 31. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country/Region (2020-2025) & ($ millions)
Table 32. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country/Region (2020-2025)
Table 33. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2025) & (K Units)
Table 34. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2020-2025)
Table 35. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 36. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2025) & (K Units)
Table 37. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application (2020-2025) & (K Units)
Table 38. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Region (2020-2025) & (K Units)
Table 39. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2020-2025)
Table 40. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Region (2020-2025) & ($ millions)
Table 41. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2025) & (K Units)
Table 42. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application (2020-2025) & (K Units)
Table 43. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2025) & (K Units)
Table 44. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 45. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2025) & (K Units)
Table 46. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application (2020-2025) & (K Units)
Table 47. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2025) & (K Units)
Table 48. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2020-2025)
Table 49. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2025) & (K Units)
Table 50. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application (2020-2025) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Group A and Group C Meningococcal Polysaccharide Vaccine
Table 52. Key Market Challenges & Risks of Group A and Group C Meningococcal Polysaccharide Vaccine
Table 53. Key Industry Trends of Group A and Group C Meningococcal Polysaccharide Vaccine
Table 54. Group A and Group C Meningococcal Polysaccharide Vaccine Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Group A and Group C Meningococcal Polysaccharide Vaccine Distributors List
Table 57. Group A and Group C Meningococcal Polysaccharide Vaccine Customer List
Table 58. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Forecast by Region (2026-2031) & (K Units)
Table 59. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Forecast by Region (2026-2031) & ($ millions)
Table 60. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales Forecast by Country (2026-2031) & (K Units)
Table 61. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 62. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales Forecast by Region (2026-2031) & (K Units)
Table 63. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 64. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Forecast by Country (2026-2031) & (K Units)
Table 65. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Forecast by Country (2026-2031) & ($ millions)
Table 66. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Forecast by Country (2026-2031) & (K Units)
Table 67. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Forecast by Country (2026-2031) & ($ millions)
Table 68. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Forecast by Type (2026-2031) & (K Units)
Table 69. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Forecast by Type (2026-2031) & ($ millions)
Table 70. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Forecast by Application (2026-2031) & (K Units)
Table 71. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Forecast by Application (2026-2031) & ($ millions)
Table 72. Walvax Basic Information, Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 73. Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 74. Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 75. Walvax Main Business
Table 76. Walvax Latest Developments
Table 77. Lanzhou Institute of Biological Products Basic Information, Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 78. Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 79. Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 80. Lanzhou Institute of Biological Products Main Business
Table 81. Lanzhou Institute of Biological Products Latest Developments
Table 82. AIM Bio Basic Information, Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 83. AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 84. AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 85. AIM Bio Main Business
Table 86. AIM Bio Latest Developments
Table 87. Sanofi Pasteur Basic Information, Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 88. Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 89. Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Sanofi Pasteur Main Business
Table 91. Sanofi Pasteur Latest Developments
Table 92. GSK Basic Information, Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 93. GSK Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 94. GSK Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 95. GSK Main Business
Table 96. GSK Latest Developments
Table 97. Hualan Bio Basic Information, Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 98. Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 99. Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 100. Hualan Bio Main Business
Table 101. Hualan Bio Latest Developments
Table 102. ZFSW Basic Information, Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 103. ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 104. ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 105. ZFSW Main Business
Table 106. ZFSW Latest Developments
Table 107. Changsheng Basic Information, Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 108. Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 109. Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 110. Changsheng Main Business
Table 111. Changsheng Latest Developments
Table 112. Kanghua Bio Basic Information, Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 113. Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 114. Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 115. Kanghua Bio Main Business
Table 116. Kanghua Bio Latest Developments
Table 1. Group A and Group C Meningococcal Polysaccharide Vaccine Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Group A and Group C Meningococcal Polysaccharide Vaccine Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Class 1 Vaccine
Table 4. Major Players of Class II Vaccine
Table 5. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2025) & (K Units)
Table 6. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2020-2025)
Table 7. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Type (2020-2025) & ($ million)
Table 8. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2020-2025)
Table 9. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Price by Type (2020-2025) & (US$/Unit)
Table 10. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale by Application (2020-2025) & (K Units)
Table 11. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Market Share by Application (2020-2025)
Table 12. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Application (2020-2025) & ($ million)
Table 13. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2020-2025)
Table 14. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Price by Application (2020-2025) & (US$/Unit)
Table 15. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Company (2020-2025) & (K Units)
Table 16. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Company (2020-2025)
Table 17. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Company (2020-2025) & ($ millions)
Table 18. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Company (2020-2025)
Table 19. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Price by Company (2020-2025) & (US$/Unit)
Table 20. Key Manufacturers Group A and Group C Meningococcal Polysaccharide Vaccine Producing Area Distribution and Sales Area
Table 21. Players Group A and Group C Meningococcal Polysaccharide Vaccine Products Offered
Table 22. Group A and Group C Meningococcal Polysaccharide Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Geographic Region (2020-2025) & (K Units)
Table 26. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share Geographic Region (2020-2025)
Table 27. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Geographic Region (2020-2025) & ($ millions)
Table 28. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Geographic Region (2020-2025)
Table 29. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country/Region (2020-2025) & (K Units)
Table 30. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Country/Region (2020-2025)
Table 31. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country/Region (2020-2025) & ($ millions)
Table 32. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country/Region (2020-2025)
Table 33. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2025) & (K Units)
Table 34. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2020-2025)
Table 35. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 36. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2025) & (K Units)
Table 37. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application (2020-2025) & (K Units)
Table 38. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Region (2020-2025) & (K Units)
Table 39. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2020-2025)
Table 40. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Region (2020-2025) & ($ millions)
Table 41. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2025) & (K Units)
Table 42. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application (2020-2025) & (K Units)
Table 43. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2025) & (K Units)
Table 44. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 45. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2025) & (K Units)
Table 46. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application (2020-2025) & (K Units)
Table 47. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2020-2025) & (K Units)
Table 48. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2020-2025)
Table 49. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type (2020-2025) & (K Units)
Table 50. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application (2020-2025) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Group A and Group C Meningococcal Polysaccharide Vaccine
Table 52. Key Market Challenges & Risks of Group A and Group C Meningococcal Polysaccharide Vaccine
Table 53. Key Industry Trends of Group A and Group C Meningococcal Polysaccharide Vaccine
Table 54. Group A and Group C Meningococcal Polysaccharide Vaccine Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Group A and Group C Meningococcal Polysaccharide Vaccine Distributors List
Table 57. Group A and Group C Meningococcal Polysaccharide Vaccine Customer List
Table 58. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Forecast by Region (2026-2031) & (K Units)
Table 59. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Forecast by Region (2026-2031) & ($ millions)
Table 60. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales Forecast by Country (2026-2031) & (K Units)
Table 61. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 62. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales Forecast by Region (2026-2031) & (K Units)
Table 63. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 64. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Forecast by Country (2026-2031) & (K Units)
Table 65. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Forecast by Country (2026-2031) & ($ millions)
Table 66. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Forecast by Country (2026-2031) & (K Units)
Table 67. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Forecast by Country (2026-2031) & ($ millions)
Table 68. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Forecast by Type (2026-2031) & (K Units)
Table 69. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Forecast by Type (2026-2031) & ($ millions)
Table 70. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Forecast by Application (2026-2031) & (K Units)
Table 71. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Forecast by Application (2026-2031) & ($ millions)
Table 72. Walvax Basic Information, Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 73. Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 74. Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 75. Walvax Main Business
Table 76. Walvax Latest Developments
Table 77. Lanzhou Institute of Biological Products Basic Information, Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 78. Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 79. Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 80. Lanzhou Institute of Biological Products Main Business
Table 81. Lanzhou Institute of Biological Products Latest Developments
Table 82. AIM Bio Basic Information, Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 83. AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 84. AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 85. AIM Bio Main Business
Table 86. AIM Bio Latest Developments
Table 87. Sanofi Pasteur Basic Information, Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 88. Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 89. Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Sanofi Pasteur Main Business
Table 91. Sanofi Pasteur Latest Developments
Table 92. GSK Basic Information, Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 93. GSK Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 94. GSK Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 95. GSK Main Business
Table 96. GSK Latest Developments
Table 97. Hualan Bio Basic Information, Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 98. Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 99. Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 100. Hualan Bio Main Business
Table 101. Hualan Bio Latest Developments
Table 102. ZFSW Basic Information, Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 103. ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 104. ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 105. ZFSW Main Business
Table 106. ZFSW Latest Developments
Table 107. Changsheng Basic Information, Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 108. Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 109. Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 110. Changsheng Main Business
Table 111. Changsheng Latest Developments
Table 112. Kanghua Bio Basic Information, Group A and Group C Meningococcal Polysaccharide Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 113. Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
Table 114. Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 115. Kanghua Bio Main Business
Table 116. Kanghua Bio Latest Developments
LIST OF FIGURES
Figure 1. Picture of Group A and Group C Meningococcal Polysaccharide Vaccine
Figure 2. Group A and Group C Meningococcal Polysaccharide Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Country/Region (2024)
Figure 10. Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Class 1 Vaccine
Figure 12. Product Picture of Class II Vaccine
Figure 13. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Type in 2025
Figure 14. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2020-2025)
Figure 15. Group A and Group C Meningococcal Polysaccharide Vaccine Consumed in Hospital
Figure 16. Global Group A and Group C Meningococcal Polysaccharide Vaccine Market: Hospital (2020-2025) & (K Units)
Figure 17. Group A and Group C Meningococcal Polysaccharide Vaccine Consumed in Clinic
Figure 18. Global Group A and Group C Meningococcal Polysaccharide Vaccine Market: Clinic (2020-2025) & (K Units)
Figure 19. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Market Share by Application (2024)
Figure 20. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application in 2025
Figure 21. Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Company in 2025 (K Units)
Figure 22. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Company in 2025
Figure 23. Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Company in 2025 ($ millions)
Figure 24. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Company in 2025
Figure 25. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Geographic Region (2020-2025)
Figure 26. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Geographic Region in 2025
Figure 27. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales 2020-2025 (K Units)
Figure 28. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Revenue 2020-2025 ($ millions)
Figure 29. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales 2020-2025 (K Units)
Figure 30. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Revenue 2020-2025 ($ millions)
Figure 31. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales 2020-2025 (K Units)
Figure 32. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Revenue 2020-2025 ($ millions)
Figure 33. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales 2020-2025 (K Units)
Figure 34. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Revenue 2020-2025 ($ millions)
Figure 35. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Country in 2025
Figure 36. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2020-2025)
Figure 37. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2020-2025)
Figure 38. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2020-2025)
Figure 39. United States Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 40. Canada Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 41. Mexico Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 42. Brazil Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 43. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Region in 2025
Figure 44. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Region (2020-2025)
Figure 45. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2020-2025)
Figure 46. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2020-2025)
Figure 47. China Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 48. Japan Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 49. South Korea Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 50. Southeast Asia Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 51. India Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 52. Australia Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 53. China Taiwan Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 54. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Country in 2025
Figure 55. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2020-2025)
Figure 56. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2020-2025)
Figure 57. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2020-2025)
Figure 58. Germany Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 59. France Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 60. UK Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 61. Italy Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 62. Russia Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 63. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2020-2025)
Figure 64. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2020-2025)
Figure 65. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2020-2025)
Figure 66. Egypt Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 67. South Africa Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 68. Israel Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 69. Turkey Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 70. GCC Countries Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 71. Manufacturing Cost Structure Analysis of Group A and Group C Meningococcal Polysaccharide Vaccine in 2025
Figure 72. Manufacturing Process Analysis of Group A and Group C Meningococcal Polysaccharide Vaccine
Figure 73. Industry Chain Structure of Group A and Group C Meningococcal Polysaccharide Vaccine
Figure 74. Channels of Distribution
Figure 75. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Forecast by Region (2026-2031)
Figure 76. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share Forecast by Region (2026-2031)
Figure 77. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share Forecast by Type (2026-2031)
Figure 78. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share Forecast by Type (2026-2031)
Figure 79. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share Forecast by Application (2026-2031)
Figure 80. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share Forecast by Application (2026-2031)
Figure 1. Picture of Group A and Group C Meningococcal Polysaccharide Vaccine
Figure 2. Group A and Group C Meningococcal Polysaccharide Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Country/Region (2024)
Figure 10. Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Class 1 Vaccine
Figure 12. Product Picture of Class II Vaccine
Figure 13. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Type in 2025
Figure 14. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2020-2025)
Figure 15. Group A and Group C Meningococcal Polysaccharide Vaccine Consumed in Hospital
Figure 16. Global Group A and Group C Meningococcal Polysaccharide Vaccine Market: Hospital (2020-2025) & (K Units)
Figure 17. Group A and Group C Meningococcal Polysaccharide Vaccine Consumed in Clinic
Figure 18. Global Group A and Group C Meningococcal Polysaccharide Vaccine Market: Clinic (2020-2025) & (K Units)
Figure 19. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Market Share by Application (2024)
Figure 20. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application in 2025
Figure 21. Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Company in 2025 (K Units)
Figure 22. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Company in 2025
Figure 23. Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Company in 2025 ($ millions)
Figure 24. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Company in 2025
Figure 25. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Geographic Region (2020-2025)
Figure 26. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Geographic Region in 2025
Figure 27. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales 2020-2025 (K Units)
Figure 28. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Revenue 2020-2025 ($ millions)
Figure 29. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales 2020-2025 (K Units)
Figure 30. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Revenue 2020-2025 ($ millions)
Figure 31. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales 2020-2025 (K Units)
Figure 32. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Revenue 2020-2025 ($ millions)
Figure 33. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales 2020-2025 (K Units)
Figure 34. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Revenue 2020-2025 ($ millions)
Figure 35. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Country in 2025
Figure 36. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2020-2025)
Figure 37. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2020-2025)
Figure 38. Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2020-2025)
Figure 39. United States Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 40. Canada Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 41. Mexico Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 42. Brazil Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 43. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Region in 2025
Figure 44. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Region (2020-2025)
Figure 45. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2020-2025)
Figure 46. APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2020-2025)
Figure 47. China Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 48. Japan Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 49. South Korea Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 50. Southeast Asia Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 51. India Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 52. Australia Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 53. China Taiwan Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 54. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Country in 2025
Figure 55. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Country (2020-2025)
Figure 56. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2020-2025)
Figure 57. Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2020-2025)
Figure 58. Germany Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 59. France Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 60. UK Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 61. Italy Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 62. Russia Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 63. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2020-2025)
Figure 64. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2020-2025)
Figure 65. Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2020-2025)
Figure 66. Egypt Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 67. South Africa Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 68. Israel Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 69. Turkey Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 70. GCC Countries Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 71. Manufacturing Cost Structure Analysis of Group A and Group C Meningococcal Polysaccharide Vaccine in 2025
Figure 72. Manufacturing Process Analysis of Group A and Group C Meningococcal Polysaccharide Vaccine
Figure 73. Industry Chain Structure of Group A and Group C Meningococcal Polysaccharide Vaccine
Figure 74. Channels of Distribution
Figure 75. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Forecast by Region (2026-2031)
Figure 76. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share Forecast by Region (2026-2031)
Figure 77. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share Forecast by Type (2026-2031)
Figure 78. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share Forecast by Type (2026-2031)
Figure 79. Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share Forecast by Application (2026-2031)
Figure 80. Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share Forecast by Application (2026-2031)
